Nuvigil launch brings up more questions about whether new isomers or metabolites of existing drugs are better than the original

July 2009

The recent Nuvigil launch brings up more questions about whether new isomers or metabolites of existing drugs are better than the original.

These "follow-on" drugs are the latest trend for drug companies looking to replace drugs with expiring patents.

But these new versions usually don't offer much improvement.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote